- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
12
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
12 companies
Gilead Sciences
Market Cap: US$166.0b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$133.69
7D
2.3%
1Y
23.3%
Illumina
Market Cap: US$22.0b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$150.17
7D
5.8%
1Y
77.9%
Exelixis
Market Cap: US$12.6b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$50.03
7D
0.3%
1Y
18.0%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$21.19
7D
1.1%
1Y
-3.8%
ADMA Biologics
Market Cap: US$1.9b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$7.92
7D
-7.5%
1Y
-59.4%
Innoviva
Market Cap: US$1.7b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$22.68
7D
4.4%
1Y
18.4%
Theravance Biopharma
Market Cap: US$846.0m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.26
7D
-1.8%
1Y
77.7%
CorMedix
Market Cap: US$648.8m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.46
7D
6.7%
1Y
-31.9%
Abeona Therapeutics
Market Cap: US$312.9m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.69
7D
7.0%
1Y
-5.0%
Compugen
Market Cap: US$250.6m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.76
7D
2.0%
1Y
90.3%
Oramed Pharmaceuticals
Market Cap: US$165.3m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.98
7D
-7.0%
1Y
84.3%
Vaxart
Market Cap: US$153.0m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
VXRT
US$0.64
7D
4.3%
1Y
41.4%